Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering,...
Day: January 3, 2024
International Consortium Publishes Comprehensive Roadmap for the Clinical Implementation of OGM in Hematological Malignancy Applications
Framework was co-authored by an international consortium made up of 18 cancer researchers Publication includes researchers’ recommendations for laboratories planning...
Dentsply Sirona to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Charlotte, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced...
Pulmocide Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
LONDON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing opelconazole for patients suffering...
Mesa Labs Completes the Acquisition of GKE Science & Technology Co.
LAKEWOOD, Colo., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa”, “we”, “us” or “our”), a global leader...
Keros Therapeutics to Develop KER-065 for the Treatment of Obesity
Keros commenced a randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial to evaluate single and multiple ascending doses of KER-065...
Pliant Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that Bernard Coulie,...
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage...
Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial Officer
Dr. Vendola Brings Deep, Hands-On Industry Strategy, Operational and Financial Expertise to the RoleST. LOUIS and SAN DIEGO, Jan. 03,...
OGM Added to International System for Human Cytogenomic Nomenclature
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced a publication outlining the addition of...
VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors
BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical...
STRATA Skin Granted Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
HORSHAM, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical...
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., founder...
Collegium Provides 2024 Financial Guidance
– Product Revenues, Net Expected in the Range of $580.0 Million to $595.0 Million – – Adjusted Operating Expenses* Expected...
Safety Shot to Garner Global Exposure with its Brand Activation Event at Coachella—One of the Top Music Festivals in the World
Safety Shot, Inc. Safety Shot to Garner Global Exposure with its Brand Activation Event at Coachella Set to be highlight...
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal...
Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
JERUSALEM, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the...
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage...
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize (50:50 profit share) AAV-delivered CRISPR/Cas-based therapeutics...
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury
TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF),...